Intestinal Metaplasia

Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis
Manoj Kumar
http://www.pitt.edu

Atrophic gastritides
http://www.pathology.med.umich.edu

Some Medical Implications of Metaplasia
http://wberesford.hsc.wvu.edu/

Histologic Variants of Urothelial Carcinoma
Jeremy S. Miller, MD
http://www.georgiahealth.edu

Benign and Malignant Esophageal Neoplasms, Perforation, Caustic Ingestion
Sara Runge, MD
http://www.medschool.ucsf.edu

Gastric Cancer
Matt White
https://medicine.med.unc.edu

Gastroesophageal Reflux Disease and Barrett’s Esophagus
Ryan D. Madanick, MD
https://medicine.med.unc.edu

Helicobacter pylori – the good, the bad and the ugly.
Kerry Williams, MD
http://hematology.im.wustl.edu

G.I. Pathology
http://student.ttuhsc.edu

GI Pathology, Case 1
http://zoomify.lumc.edu

Disorders of the Esophagus
Adriana Acurio M.D.
http://cmspath.edu/

Clinical Relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin
Gerhard, M., Lehn, N., et al.
http://snhs-plin.barry.edu


204 Published articles articles on Intestinal Metaplasia

1. Expression of MUC5AC and Trefoil Peptide 1 (TFF1) in the Subtypes of Intestinal Metaplasia.
2. Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma.
3. Chronic gastritis with intestinal metaplasia: clinico-statistical, histological and immunohistochemical study.
4. Relation between reflux of bile acids into the stomach and gastric mucosal atrophy, intestinal metaplasia in biopsy specimens.
5. Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia.
6. MicroRNAs up-regulated by CagA of Helicobacter pylori induce intestinal metaplasia of gastric epithelial cells.
7. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis.
8. Follow-up of intestinal metaplasia in the stomach: When, how and why.
9. The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry.
10. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment.
11. Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study.
12. Helicobacter pylori with stronger intensity of CagA phosphorylation lead to an increased risk of gastric intestinal metaplasia and cancer.
13. CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer.
14. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study.
15. Detection of intestinal metaplasia after successful eradication of Barrett's Esophagus with radiofrequency ablation.
16. Non-sequential narrow band imaging for targeted biopsy and monitoring of gastric intestinal metaplasia.
17. Long-term administration of the fungus toxin, sterigmatocystin, induces intestinal metaplasia and increases the proliferative activity of PCNA, p53, and MDM2 in the gastric mucosa of aged Mongolian gerbils.
18. Magnification endoscopy and chromoendoscopy in evaluation of specialized intestinal metaplasia in Barrett's Esophagus.
19. Short-segment Barrett's esophagus and cardia intestinal metaplasia: A comparative analysis.
20. Intestinal metaplasia of the renal pelvis.
21. CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype.
22. Is the prevalence of intestinal metaplasia at the squamocolumnar junction different in patients with progressive systemic sclerosis?
23. Intestinal metaplasia -the effect of Acid on the gastric mucosa and gastric carcinogenesis-.
24. Lack of clinical usefulness of Das-1 monoclonal antibody and mucin expression as risk markers of gastric carcinoma in patients with gastric intestinal metaplasia.
25. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy.
26. Inflammatory cytokine gene polymorphisms increase the risk of atrophic gastritis and intestinal metaplasia.
27. Pathology of gastric intestinal metaplasia: clinical implications.
28. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.
29. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.
30. Adenomatous polyp with intestinal metaplasia of the esophagus (Barrett esophagus) in a dog.
31. Increased lysozyme expression in gastric biopsies with intestinal metaplasia and pseudopyloric metaplasia.
32. Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study.
33. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas.
34. Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression.
35. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.
36. Host Wnt/beta-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication.
37. The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer.
38. Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and intestinal metaplasia.
39. Lack of clinical usefulness of Das-1 monoclonal antibody and mucin expression as risk markers of gastric carcinoma in patients with gastric intestinal metaplasia.
40. [The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age and Helicobacter pylori infection in a rural population].
41. Analysis of R213R and 13494 g-->a polymorphisms of the p53 gene in individuals with esophagitis, intestinal metaplasia of the cardia and Barrett's Esophagus compared with a control group.
42. Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.
43. Intestinal metaplasia in gallbladders: prevalence study.
44. Systematic review of the prevalence of gastric intestinal metaplasia and its area-level association with smoking.
45. Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum.
46. Clinicopathologic implications of genetic instability in intestinal-type gastric cancer and intestinal metaplasia as a precancerous lesion: proof of field cancerization in the stomach.
47. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
48. [Clinical observation of Zhihua Decoction in treatment of atrophic gastritis complicated by intestinal metaplasia and dysplasia: a report of 78 cases].
49. How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus?
50. [Histological changes of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication].
51. Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder.
52. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer.
53. Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma.
54. Prevalence and topography of intestinal metaplasia in columnar lined esophagus.
55. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype.
56. [Microarray analysis of multiple gene expression in intestinal metaplasia and atrophic gastritis].
57. [Gene expression profiling using oligonucleotide microarray in atrophic gastritis and intestinal metaplasia].
58. Smoking, Helicobacter pylori virulence, and type of intestinal metaplasia in Portuguese males.
59. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
60. Sporadic ganglioneuromatosis of esophagogastric junction in a patient with gastro-esophageal reflux disorder and intestinal metaplasia.
61. Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography.
62. Short segment Barrett's esophagus and distal gastric intestinal metaplasia.
63. Methylation of multiple genes in gastric glands with intestinal metaplasia: A disorder with polyclonal origins.
64. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
65. K-ras mutations and cell kinetics in Helicobacter pylori associated gastric intestinal metaplasia: a comparison before and after eradication in patients with chronic gastritis and gastric cancer.
66. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder.
67. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
68. Diagnostic accuracy of magnifying chromoendoscopy with detection of intestinal metaplasia and dysplasia using acetic acid in Barrett's esophagus.
69. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
70. Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis.
71. [Expression of intestine-specific transcription factor CDX2 in different subtypes of intestinal metaplasia and gastric carcinoma].
72. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy.
73. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
74. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study.
75. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
76. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients.
77. Extensive intestinal metaplasia in gastric carcinoma and in other lesions requiring surgery: a study of 3,421 gastrectomy specimens from dwellers of the Atlantic and Pacific basins.
78. Gastric heterotopia together with intestinal metaplasia in the gallbladder: case report and review of literature.
79. Mucin phenotypic expression and p53 gene abnormality of gastric super-minute well-differentiated adenocarcinoma: re-evaluation with relationship between histogenesis of well-differentiated adenocarcinoma and intestinal metaplasia in distal stomach.
80. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection.
81. Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China.
82. Relationship between beta-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia.
83. Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia.
84. Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract.
85. Intestinal metaplasia with a high salt diet induces epithelial proliferation and alters cell composition in the gastric mucosa of mice.
86. Evaluation of initial and deeper sections of esophageal biopsy specimens for detection of intestinal metaplasia.
87. Gastritis-associated adenocarcinoma and intestinal metaplasia in a Syrian hamster naturally infected with Helicobacter species.
88. Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
89. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.
90. Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer.
91. Pericryptal fibroblast sheath in intestinal metaplasia and gastric carcinoma.
92. Helicobacter-induced intestinal metaplasia in the stomach correlates with Elk-1 and serum response factor induction of villin.
93. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
94. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice.
95. Extended intestinal metaplasia. A survey of 1392 gastrectomies from dwellers of the Pacific basin.
96. [Expression of Cdx-2 homeobox gene in intestinal metaplasia and gastric adenocarcinoma].
97. The relation of Helicobacter pylori with intestinal metaplasia, gastric atrophy and BCL-2.
98. Gene expression profiling in Barrett's esophagus and cardia intestinal metaplasia: a comparative analysis using cDNA microarray.
99. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
100. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice.
101. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
102. Gastric intestinal metaplasia.
103. Alteration of E-cadherin expression in gastric mucosa: role of intestinal metaplasia and Helicobacter pylori infection.
104. [Specialized intestinal metaplasia of the distal esophagus in gastroesophageal reflux disease: prevalence and clinico-demographic features].
105. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis.
106. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.
107. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable?
108. Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction.
109. Intestinal metaplasia: evolution after Helicobacter pylori eradication and influence in the success of eradicating therapy.
110. Phenotypic differences between esophageal and gastric intestinal metaplasia.
111. The association of short segment Barrett's esophagus with intestinal metaplasia in stomach.
112. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells.
113. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation.
114. Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope.
115. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma.
116. MUC1 polymorphism confers increased risk for intestinal metaplasia in a Colombian population with chronic gastritis.
117. Increased apoptosis in gastric mucosa adjacent to intestinal metaplasia.
118. Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma.
119. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia.
120. Helicobacter pylori and telomerase activity in intestinal metaplasia of the stomach.
121. Inflammation and intestinal metaplasia at the squamocolumnar junction in young patients with or without Helicobacter pylori infection.
122. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus.
123. Is intestinal metaplasia of the stomach reversible?
124. Risk of gastric carcinoma in patients with atrophic gastritis and intestinal metaplasia.
125. Cytokeratin immunoreactivity of intestinal metaplasia.
126. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis.
127. p53 mutations and microsatellite instabilities in the subtype of intestinal metaplasia of the stomach.
128. Bile reflux gastritis and intestinal metaplasia at the cardia.
129. Review article: intestinal metaplasia and gastric carcinogenesis.
130. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
131. Intestinal metaplasia with dysplasia in pelvis of a horse-shoe kidney.
132. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
133. Intestinal metaplasia of the esophagus or esophagogastric junction: evidence of distinct clinical, pathologic, and histochemical staining features.
134. Induction of intestinal metaplasia in stomach of dogs and expression of tumor-related proteins in animal gastric mucosa lesions.
135. Collagenous gastritis: a long-term follow-up with the development of endocrine cell hyperplasia, intestinal metaplasia, and epithelial changes indeterminate for dysplasia.
136. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
137. Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery.
138. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia.
139. Apoptosis and proliferation in Helicobacter pylori-associated gastric intestinal metaplasia.
140. Gastric intestinal metaplasia: subtypes and natural history.
141. Prolonged measurement of lower oesophageal sphincter function in patients with intestinal metaplasia at the oesophagogastric junction.
142. The subtleties of intestinal metaplasia.
143. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia.
144. Comparison of precancerous conditions: atrophy and intestinal metaplasia in Helicobacter pylori gastritis among Chinese and Dutch patients.
145. Heterotopic gastric mucosa together with intestinal metaplasia and moderate dysplasia in the gall bladder: report of two clinically unusual cases with literature review.
146. Intestinal metaplasia in patients with columnar lined esophagus is associated with high levels of duodenogastroesophageal reflux.
147. Gastritis and intestinal metaplasia in Syrian hamsters infected with Helicobacter aurati and two other microaerobes.
148. Gastric cardia intestinal metaplasia: biopsy follow-up of 85 patients.
149. Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study.
150. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus.
151. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer.
152. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.
153. Expression of an intestine-specific transcription factor (CDX1) in intestinal metaplasia and in subsequently developed intestinal type of cholangiocarcinoma in rat liver.
154. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer.
155. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia.
156. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis.
157. Adherence of Helicobacter pylori to areas of type II intestinal metaplasia in Korean gastric mucosa.
158. Mutagenic activation of environmental carcinogens by microsomes of gastric mucosa with intestinal metaplasia.
159. Study of gastric carcinomas with special reference to intestinal metaplasia.
160. Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils.
161. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
162. The impact of an antireflux procedure on intestinal metaplasia of the cardia.
163. Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease?
164. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer.
165. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia.
166. Short segments of Barrett's epithelium and intestinal metaplasia in normal appearing oesophagogastric junctions: the same or two different entities?
167. Intestinal metaplasia and the squamocolumnar junction: what does it all mean?
168. Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers.
169. Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy.
170. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease.
171. Decrease of ornithine decarboxylase activity in premalignant gastric mucosa and regression of small intestinal metaplasia in patients supplemented with high doses of vitamin E.
172. Lewis, secretor, and ABO phenotypes, and sulfomucin expression in gastric intestinal metaplasia.
173. Immunohistochemical evaluation of keratin 20 expression in intestinal metaplasia types I to III.
174. Inverse relation of serum Helicobacter pylori antibody titres and extent of intestinal metaplasia.
175. Demonstration of a field defect in gastric intestinal metaplasia by biological marker analysis.
176. [Gastric ulcer and patterns of distribution of intestinal metaplasia in the elderly].
177. Bile reflux and intestinal metaplasia in gastric mucosa.
178. Helicobacter pylori and gastric cancer: correlation with gastritis, intestinal metaplasia, and tumour histology.
179. Subtypes of intestinal metaplasia and Helicobacter pylori.
180. Gastric intestinal metaplasia in ethnic groups in the southwestern United States.
181. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum.
182. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up.
183. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study.
184. Is intestinal metaplasia a risk for gastric carcinoma?
185. Method to quantitate intestinal metaplasia of stomach by image analysis.
186. Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma.
187. Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine.
188. [Aging signs in the gastrointestinal tract--endoscopic diagnosis and the significance of gastric intestinal metaplasia].
189. Histopathogenesis of intestinal metaplasia: minute lesions of intestinal metaplasia in ulcerated stomachs.
190. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.
191. Intestinal metaplasia in endoscopic biopsy specimens of gastric mucosa.
192. Age-related trends of gastritis and intestinal metaplasia in gastric carcinoma patients and in controls representing the population at large.
193. Independent induction of intestinal metaplasia and gastric cancer in rats treated with N-methyl-N'-nitro-N-nitrosoguanidine.
194. Aroclor 1254-induced intestinal metaplasia and adenocarcinoma in the glandular stomach of F344 rats.
195. Role of intestinal metaplasia in the histogenesis of gastric carcinoma.
196. Endocrine cells in the intestinal metaplasia of gastric mucosa.
197. A study of gastric carcinoma among Koreans with special reference to the pathogenetic relation of intestinal metaplasia.
198. Blood group activity of human sucrase from intestinal metaplasia.
199. Alkaline phosphatase isoenzymes in intestinal metaplasia and carcinoma of the stomach.
200. [Aging and appearance of intestinal metaplasia in chronic gastritis].
201. ABO blood groups, rhesus factor and intestinal metaplasia of the stomach.
202. Cytological studies on the enterochromaffin cells in the intestinal metaplasia.
203. Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa.
204. Intestinal metaplasia of the gastric mucosa.